Outlook Therapeutics Q2 Revenue $128,000
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Reports Q2 revenue $128,000, consensus $4.4M. "We remain committed to working collaboratively with the FDA to establish a clear path forward toward potential U.S. approval. Our objective is clear: to bring the first FDA-approved ophthalmic formulation of bevacizumab to patients in the United States," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "In addition, we are encouraged by the continued momentum of our European commercial launch of LYTENAVA, highlighted by our expansion into new markets, as well as our recently announced partnership in Switzerland and growing physician adoption in our initial launch countries."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OTLK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OTLK
Wall Street analysts forecast OTLK stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.740
Low
0.50
Averages
3.83
High
10.00
Current: 0.740
Low
0.50
Averages
3.83
High
10.00
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves Eye Disease Drug Lytenava, Shares Surge
- FDA Approval: The FDA granted approval to Outlook Therapeutics' eye disease drug Lytenava on Tuesday, which has already been approved in the EU and UK, marking a significant advancement in treating wet age-related macular degeneration.
- Stock Surge: Following the FDA approval announcement, Outlook Therapeutics' share price soared 140% on Thursday, on track for its best week since listing, reflecting strong investor optimism regarding the drug's potential.
- Future Plans: Outlook Therapeutics plans to resubmit its Biologics License Application (BLA) in June 2026, expecting a Class 1 review with a regulatory decision possible within 60 days post-resubmission, indicating confidence in future market opportunities.
- Insider Buying: Director Randy H. Thurman purchased 5,000 shares at $0.429 each on Wednesday, along with three other directors, demonstrating strong insider confidence in the company's prospects.
See More
Outlook Therapeutics Completes Stock Offering
- Stock Offering Details: Outlook Therapeutics announced a registered direct offering of 8,539,709 shares at $0.5855 per share to GMS Ventures, expecting gross proceeds of $5 million, which will be allocated for working capital and general corporate purposes.
- Subscription Agreement: This offering is conducted under Nasdaq rules and is expected to close on May 29, 2026, marking a proactive step in capital markets that enhances the company's financial flexibility.
- Warrant Adjustment: The company agreed to amend previously issued warrants to GMS Ventures, reducing the exercise price from $1.78 to $0.5855, which is expected to further incentivize investor participation and boost market confidence.
- Market Outlook: If approved in the U.S., ONS-5010/LYTENAVA™ would be the first ophthalmic formulation of bevacizumab for retinal diseases, presenting significant market potential and strengthening the company's competitive position in the biopharmaceutical sector.
See More
Outlook Therapeutics Prices $5 Million Stock Offering
- Offering Details: Outlook Therapeutics announced a registered direct offering of 8,539,709 shares at $0.5855 each to its largest shareholder, GMS Ventures, expected to close around May 29, 2026, aiming to raise $5 million for working capital and general corporate purposes.
- Existing Registration Statement: The securities are sold under an existing shelf registration statement on Form S-3, originally filed in March 2024 and effective in April 2024, indicating the company's compliance and transparency in capital markets, which enhances investor confidence.
- Warrant Amendment: As part of the transaction, Outlook Therapeutics agreed to amend previously issued warrants held by GMS Ventures, reducing the exercise price to $0.5855 per share, aimed at improving shareholder returns and facilitating future financing.
- Stock Performance Review: Over the past year, Outlook Therapeutics' stock has traded between $0.16 and $3.39, closing at $0.74, up 26.39% from the previous trading day, reflecting positive market expectations for the company's future developments.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
Multiple Companies See Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
RDW Stock Rises 26% Amid Space Sector Euphoria Following SpaceX Debut
- RDW Stock Surge: Redwire Corp. (RDW) shares rose 26%, driven by the excitement surrounding SpaceX's market debut, positioning the company for its best monthly performance ever with nearly a 140% increase in May.
- TE Shareholder Boost: T1 Energy Inc. (TE) stock jumped over 29% after major shareholder Trina Solar received an additional 4.27 million shares, raising total holdings to over 53 million, reflecting strong institutional support and market confidence, with an impressive 816% rise over the past year.
- OTLK FDA Victory: Outlook Therapeutics Inc. (OTLK) shares soared 29% following a significant regulatory win from the FDA for its eye disease drug Lytenava, with plans to resubmit its Biologics License Application in June 2026, potentially making it the first FDA-approved ophthalmic formulation for retinal diseases in the U.S.
- Market Sentiment Extremely Bullish: Retail sentiment for RDW, TE, and OTLK has remained in the 'extremely bullish' territory over the past three months, with RDW's message volume on Stocktwits increasing by 552.6%, indicating strong investor interest in the space and biopharma sectors.
See More
FDA Approves Eye Disease Drug Lytenava, Shares Surge
- FDA Approval: The FDA granted approval to Outlook Therapeutics' eye disease drug Lytenava on Tuesday, which has already been approved in the EU and UK, marking a significant advancement in treating wet age-related macular degeneration.
- Stock Surge: Following the FDA approval announcement, Outlook Therapeutics' share price soared 140% on Thursday, on track for its best week since listing, reflecting strong investor optimism regarding the drug's potential.
- Future Plans: Outlook Therapeutics plans to resubmit its Biologics License Application (BLA) in June 2026, expecting a Class 1 review with a regulatory decision possible within 60 days post-resubmission, indicating confidence in future market opportunities.
- Insider Buying: Director Randy H. Thurman purchased 5,000 shares at $0.429 each on Wednesday, along with three other directors, demonstrating strong insider confidence in the company's prospects.
See More
Outlook Therapeutics Completes Stock Offering
- Stock Offering Details: Outlook Therapeutics announced a registered direct offering of 8,539,709 shares at $0.5855 per share to GMS Ventures, expecting gross proceeds of $5 million, which will be allocated for working capital and general corporate purposes.
- Subscription Agreement: This offering is conducted under Nasdaq rules and is expected to close on May 29, 2026, marking a proactive step in capital markets that enhances the company's financial flexibility.
- Warrant Adjustment: The company agreed to amend previously issued warrants to GMS Ventures, reducing the exercise price from $1.78 to $0.5855, which is expected to further incentivize investor participation and boost market confidence.
- Market Outlook: If approved in the U.S., ONS-5010/LYTENAVA™ would be the first ophthalmic formulation of bevacizumab for retinal diseases, presenting significant market potential and strengthening the company's competitive position in the biopharmaceutical sector.
See More
Outlook Therapeutics Prices $5 Million Stock Offering
- Offering Details: Outlook Therapeutics announced a registered direct offering of 8,539,709 shares at $0.5855 each to its largest shareholder, GMS Ventures, expected to close around May 29, 2026, aiming to raise $5 million for working capital and general corporate purposes.
- Existing Registration Statement: The securities are sold under an existing shelf registration statement on Form S-3, originally filed in March 2024 and effective in April 2024, indicating the company's compliance and transparency in capital markets, which enhances investor confidence.
- Warrant Amendment: As part of the transaction, Outlook Therapeutics agreed to amend previously issued warrants held by GMS Ventures, reducing the exercise price to $0.5855 per share, aimed at improving shareholder returns and facilitating future financing.
- Stock Performance Review: Over the past year, Outlook Therapeutics' stock has traded between $0.16 and $3.39, closing at $0.74, up 26.39% from the previous trading day, reflecting positive market expectations for the company's future developments.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
Multiple Companies See Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
RDW Stock Rises 26% Amid Space Sector Euphoria Following SpaceX Debut
- RDW Stock Surge: Redwire Corp. (RDW) shares rose 26%, driven by the excitement surrounding SpaceX's market debut, positioning the company for its best monthly performance ever with nearly a 140% increase in May.
- TE Shareholder Boost: T1 Energy Inc. (TE) stock jumped over 29% after major shareholder Trina Solar received an additional 4.27 million shares, raising total holdings to over 53 million, reflecting strong institutional support and market confidence, with an impressive 816% rise over the past year.
- OTLK FDA Victory: Outlook Therapeutics Inc. (OTLK) shares soared 29% following a significant regulatory win from the FDA for its eye disease drug Lytenava, with plans to resubmit its Biologics License Application in June 2026, potentially making it the first FDA-approved ophthalmic formulation for retinal diseases in the U.S.
- Market Sentiment Extremely Bullish: Retail sentiment for RDW, TE, and OTLK has remained in the 'extremely bullish' territory over the past three months, with RDW's message volume on Stocktwits increasing by 552.6%, indicating strong investor interest in the space and biopharma sectors.
See More
